| Stuart E Shulruff, MD | |
|
356 Route 46 E, Mountain Lakes, NJ 07046-1717 | |
| (973) 586-3400 | |
| (973) 586-1916 |
| Full Name | Stuart E Shulruff |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 46 Years |
| Location | 356 Route 46 E, Mountain Lakes, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871590448 | NPI | - | NPPES |
| 3723003 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 25MA04200900 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Clare's Hospital/ Denville Campus | Denville, NJ | Hospital |
| Morristown Medical Center | Morristown, NJ | Hospital |
| Newton Medical Center | Newton, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Practice Associates Medical Group | 5890703177 | 1116 |
News Archive
Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.
Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.
By coupling a kicked-up version of microscopy with gold nanoparticles, investigators at Duke University have been able to peer so deeply into living tissue that they can see molecules interacting.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.
The global public health community must take action to scale up services for mental disorders, especially in low- and middle-income (LAMI) countries, according to a team of public health experts writing in the Lancet.
› Verified 1 days ago
| Entity Name | Practice Associates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427016385 PECOS PAC ID: 5890703177 Enrollment ID: O20060330000690 |
News Archive
Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.
Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.
By coupling a kicked-up version of microscopy with gold nanoparticles, investigators at Duke University have been able to peer so deeply into living tissue that they can see molecules interacting.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.
The global public health community must take action to scale up services for mental disorders, especially in low- and middle-income (LAMI) countries, according to a team of public health experts writing in the Lancet.
› Verified 1 days ago
| Entity Name | Cardiology Consultants Of North Morris, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427056217 PECOS PAC ID: 3173699956 Enrollment ID: O20081206000074 |
News Archive
Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.
Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.
By coupling a kicked-up version of microscopy with gold nanoparticles, investigators at Duke University have been able to peer so deeply into living tissue that they can see molecules interacting.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.
The global public health community must take action to scale up services for mental disorders, especially in low- and middle-income (LAMI) countries, according to a team of public health experts writing in the Lancet.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stuart E Shulruff, MD Po Box 416457, Boston, MA 02241-6457 Ph: () - | Stuart E Shulruff, MD 356 Route 46 E, Mountain Lakes, NJ 07046-1717 Ph: (973) 586-3400 |
News Archive
Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.
Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.
By coupling a kicked-up version of microscopy with gold nanoparticles, investigators at Duke University have been able to peer so deeply into living tissue that they can see molecules interacting.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.
The global public health community must take action to scale up services for mental disorders, especially in low- and middle-income (LAMI) countries, according to a team of public health experts writing in the Lancet.
› Verified 1 days ago
Christopher Michael Tully, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 333 Route 46 W, Mountain Lakes, NJ 07046 Phone: 973-316-1701 Fax: 973-316-1708 | |
Ronald D Massari, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 356 Route 46 E, Mountain Lakes, NJ 07046 Phone: 973-586-3400 Fax: 973-586-1916 | |
Keith S Leibowitz, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 415 Boulevard, Mountain Lakes, NJ 07046 Phone: 973-334-7700 Fax: 973-402-5847 | |
Paul D Derenzi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 415 Boulevard, Mountain Lakes, NJ 07046 Phone: 973-334-7700 Fax: 973-402-5847 | |
Philip S Rogers, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 415 Boulevard, Mountain Lakes, NJ 07046 Phone: 973-334-7700 Fax: 973-402-5847 | |
Hyeun S Park, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 415 Boulevard, Mountain Lakes, NJ 07046 Phone: 973-334-7700 Fax: 973-334-7116 | |
Dr. Muhammad R. Abbasi, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 333 Route 46 W, Mountain Lakes, NJ 07046 Phone: 973-316-1701 Fax: 973-316-1708 |